PTC Therapeutics (NASDAQ: PTCT) director trades 733 shares after option exercise

Rhea-AI Filing Summary

PTC Therapeutics, Inc. director reports option exercise and share sale. On 12/03/2025, the director exercised a stock option for 733 shares of common stock at $46.54 per share and then sold 733 common shares at $78.62 per share. After these transactions, the director directly beneficially owned 6,666 shares of PTC Therapeutics common stock.

The stock option exercised on that date had a conversion price of $46.54 and relates to 733 underlying common shares. Following the transaction, the director held 734 derivative securities (stock options) expiring on 01/02/2035. The filing notes that the transaction was effected under a written Rule 10b5-1 trading plan adopted on March 4, 2025, which is designed to standardize trading and help address trading‑window and insider‑trading concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reeve Emma

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		M(1)		733	A	$46.54	7,399	D
Common Stock	12/03/2025		S(1)		733	D	$78.62	6,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.54	12/03/2025		M(1)			733	(2)	01/02/2035	Common Stock	733	$0	734	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.

2. This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025.

	/s/ Avraham S. Adler, Attorney-in-Fact	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did the PTC Therapeutics (PTCT) director report on this Form 4?

The director reported exercising a stock option for 733 shares of PTC Therapeutics common stock at $46.54 per share and selling 733 common shares at $78.62 per share on 12/03/2025.

How many PTC Therapeutics (PTCT) shares does the director own after the reported transaction?

After the reported transactions, the director directly beneficially owned 6,666 shares of PTC Therapeutics common stock.

What stock options does the PTC Therapeutics (PTCT) director still hold after this Form 4?

Following the transaction, the director held 734 derivative securities in the form of stock options with an exercise price of $46.54 per share, expiring on 01/02/2035.

Was the PTC Therapeutics (PTCT) director’s trade made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2025.

What does the transaction code on the PTC Therapeutics (PTCT) Form 4 indicate?

The Form 4 uses code M for the exercise of a stock option and code S for the sale of the resulting common shares, both occurring on 12/03/2025.

What is the director’s relationship to PTC Therapeutics (PTCT) as disclosed in the Form 4?

The reporting person is identified as a Director of PTC Therapeutics, Inc., with the Form 4 filed by one reporting person.